Ｂ型肝炎ウイルスの再活性化の現状

DOI HANDLE Web Site オープンアクセス

書誌事項

タイトル別名
  • Prevention and Management of Hepatitis B Virus Reactivation
  • Bガタ カンエンウイルス ノ サイカッセイカ ノ ゲンジョウ

この論文をさがす

抄録

Globally, it is estimated that around 1 in every 3 individuals may have been exposed to hepatitis B virus(HBV) infection. In addition, population of 6％ are chronic carriers and over 600,000 people die each year from acute hepatitis, liver cirrhosis or hepatocellular carcinoma due to HBV infection. Recently, HBV reactivation associated with immune-suppressive and biological therapies is emerging to be an important cause of morbidity and mortality in patients with prior exposure to HBV infection. With the advent of newer and emerging forms of cancer chemotherapy, immunosuppressive or biologic therapies, it has become important to understand the mechanisms whereby certain therapies are more prone to HBV reactivation. In this article, we summarize the mechanism of HBV reactivation associated with immune-suppressive and biological therapies.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ